Do all patients with coronary artery disease benefit from angiotensin converting enzyme inhibitors?

Area of Science:

• Cardiology
• Pharmacology

Background:

• Angiotensin-converting enzyme (ACE) inhibitors are established treatments for stable coronary artery disease (CAD).
• Patient populations include those with and without heart failure.
• Variability in clinical outcomes may stem from differing ACE inhibitor properties, dosages, trial designs, and demographics.

Purpose of the Study:

• To review the evidence supporting ACE inhibitor use in stable coronary artery disease.
• To explore factors contributing to variable patient responses to ACE inhibitors.
• To provide recommendations for secondary risk prevention.

Main Methods:

• Review of cumulative clinical trial data on ACE inhibitors in stable coronary artery disease.
• Analysis of factors influencing treatment efficacy, including drug properties and trial characteristics.
• Evaluation of evidence for specific ACE inhibitors like ramipril and perindopril.

Main Results:

• Consistent evidence supports ACE inhibitor use across diverse patient groups with stable CAD.
• Dose, specific drug properties, trial design, and patient demographics influence clinical outcomes.
• Ramipril and perindopril demonstrate efficacy for secondary risk prevention.

Conclusions:

• ACE inhibitors are beneficial for secondary risk prevention in stable coronary artery disease.
• Ramipril and perindopril are recommended agents pending direct comparative trials.
• Further research comparing tissue and plasma ACE inhibitors is warranted.